47.10

0.86% -0.41

Janux Therapeutics Inc (JANX)

Overview News Price History Option Chain Financials Discussions Forecast

Janux Therapeutics Inc stock is currently priced at $47.10, with a 24-hour trading volume of 587.58K. It has seen a -0.86% decreased in the last 24 hours and a -1.79% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $47.44 pivot point. If it approaches the $46.64 support level, significant changes may occur.

Previous Close:

$47.51

Open:

$47.76

24h Volume:

587.58K

Market Cap:

$2.44B

Revenue:

$8.08M

Net Income/Loss:

$-58.29M

P/E Ratio:

-28.90

EPS:

-1.63

Net Cash Flow:

$-52.43M

1W Performance:

-3.72%

1M Performance:

-1.79%

6M Performance:

+442.63%

1Y Performance:

+292.50%

1D Range:

$46.79

$47.97

52W Range:

$5.65

$65.60

Janux Therapeutics Inc Stock (JANX) Company Profile

Name

Janux Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

858-750-4700

Address

11099 North Torrey Pines Road, Suite 290, La Jolla

Employee

Twitter

Next Earnings Date

2024-05-10

Latest SEC Filings

JANX's Discussions on Twitter

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-06-23	Initiated	Wedbush	Outperform
Nov-14-22	Initiated	William Blair	Outperform

Janux Therapeutics Inc Stock (JANX) Latest News

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Could Be 28% Below Their Intrinsic Value Estimate - Yahoo Movies UK

Yahoo Movies UK

HC Wainwright Equities Analysts Lower Earnings Estimates for Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat

MarketBeat

Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasted to Post Q2 2024 Earnings of ($0.38) Per Share - Defense World

Defense World

Janux Therapeutics (NASDAQ:JANX) PT Raised to $63.00 - Defense World

Defense World

Janux Therapeutics (NASDAQ:JANX) Trading Down 3.1% - MarketBeat

MarketBeat

Ready to Jump After Recent Trade: Janux Therapeutics Inc (JANX) – Sete News - SETE News

SETE News

Janux Therapeutics Inc Stock (JANX) Financials Data

Janux Therapeutics Inc (JANX) Revenue 2024

JANX reported a revenue (TTM) of $8.08 million for the quarter ending December 31, 2023, a -6.14% decline year-over-year.

Janux Therapeutics Inc (JANX) Net Income 2024

JANX net income (TTM) was -$58.29 million for the quarter ending December 31, 2023, a +7.56% increase year-over-year.

Janux Therapeutics Inc (JANX) Cash Flow 2024

JANX recorded a free cash flow (TTM) of -$52.42 million for the quarter ending December 31, 2023, a -6.19% decrease year-over-year.

Janux Therapeutics Inc (JANX) Earnings per Share 2024

JANX earnings per share (TTM) was -$1.33 for the quarter ending December 31, 2023, a +12.50% growth year-over-year.

Janux Therapeutics Inc Stock (JANX) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Avalon Ventures XI, L.P.	10% Owner	Nov 13 '23	Buy	5.87	849,854	4,988,643	849,854
Reardon Tighe	Acting Chief Financial Officer	Nov 13 '23	Buy	5.87	849,854	4,988,643	849,854
Lichter Jay	Director	Nov 13 '23	Buy	5.87	849,854	4,988,643	849,854
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 19 '23	Buy	12.46	495,008	6,167,800	8,117,246

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.